Heidelberg Pharma AG Investor Relations Material
Heidelberg Pharma is a biopharmaceutical company that focuses on oncology and antibody targeted amanitin conjugates (ATAC). Their innovations are based on cell immunotherapy and the drug amanitin conjugates (ATAC). The tumor cells are attacked by immune cells, which recognize the amanitin antigen as a foreign body. This way the treatment causes no mutilation of healthy tissue
Upcoming events for
Q3 20222022-10-13
Q2 20222022-07-14
Latest company events
Ticker symbol
HPHA
Country
Germany
About the company
Investor Relations Page
https://heidelberg-pharma.com/de/presse-investoren/mitteilungen/finanzberichte
Dig deeper into the Heidelberg Pharma AG fundamentals on Quartr.
- Skip straight to the Q&A session
- Receive notifications about new events
- Connect the financial calender on your phone
- Figure out why the stock is up or down
- Read the transcripts or scroll the deck
- Access earnings or press releases
